This is likely driven by the high frequency of RB1 mutations, elevated TGF-β expression, and increased immunosuppressive gene expression, all of which contribute to a profoundly suppressive tumor microenvironment that ablates T cell anti-tumor activity. The gene discussed is TGFB1; the disease is neoplasm.